HB Wealth Management LLC Grows Position in Johnson & Johnson (NYSE:JNJ)

HB Wealth Management LLC lifted its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 1.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 207,479 shares of the company's stock after purchasing an additional 3,460 shares during the quarter. HB Wealth Management LLC's holdings in Johnson & Johnson were worth $30,003,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. Pacer Advisors Inc. raised its stake in shares of Johnson & Johnson by 15.3% in the second quarter. Pacer Advisors Inc. now owns 240,605 shares of the company's stock valued at $35,167,000 after buying an additional 31,908 shares during the period. Kowal Investment Group LLC boosted its holdings in Johnson & Johnson by 1.2% in the 2nd quarter. Kowal Investment Group LLC now owns 9,888 shares of the company's stock worth $1,445,000 after buying an additional 121 shares during the period. ProShare Advisors LLC raised its holdings in Johnson & Johnson by 9.8% during the 2nd quarter. ProShare Advisors LLC now owns 1,651,733 shares of the company's stock valued at $241,417,000 after acquiring an additional 147,609 shares during the period. Prospector Partners LLC boosted its holdings in shares of Johnson & Johnson by 1.0% in the second quarter. Prospector Partners LLC now owns 66,134 shares of the company's stock worth $9,666,000 after acquiring an additional 660 shares during the period. Finally, Frank Rimerman Advisors LLC grew its holdings in Johnson & Johnson by 1,811.6% during the 2nd quarter. Frank Rimerman Advisors LLC now owns 31,541 shares of the company's stock valued at $4,610,000 after buying an additional 29,891 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ traded down $0.74 during midday trading on Monday, hitting $147.03. The company had a trading volume of 10,678,393 shares, compared to its average volume of 6,880,262. The company has a fifty day moving average of $148.51 and a two-hundred day moving average of $156.10. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The company has a market cap of $353.99 billion, a price-to-earnings ratio of 21.28, a PEG ratio of 2.30 and a beta of 0.51.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.37%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson's payout ratio is 71.78%.

Insider Transactions at Johnson & Johnson

In other news, Director Mark A. Weinberger bought 1,000 shares of the company's stock in a transaction that occurred on Thursday, December 12th. The stock was bought at an average price of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now owns 1,000 shares of the company's stock, valued at approximately $147,220. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.16% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Wolfe Research began coverage on shares of Johnson & Johnson in a report on Friday, November 15th. They issued an "outperform" rating and a $190.00 price target on the stock. Guggenheim boosted their price target on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a "neutral" rating in a research report on Wednesday, November 6th. Bank of America decreased their price objective on Johnson & Johnson from $166.00 to $160.00 and set a "neutral" rating on the stock in a report on Friday. Royal Bank of Canada upped their target price on Johnson & Johnson from $178.00 to $181.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 16th. Finally, Citigroup decreased their price target on shares of Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating on the stock in a research note on Wednesday, December 11th. Seven equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $174.29.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.